| NCT05092360 | Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) | TERMINATED | PHASE3 | 2022-01-10 | 2025-05-08 | 2025-01-08 |
| NCT04830124 | Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6 | TERMINATED | PHASE2 | 2021-09-27 | 2025-05-08 | 2025-05-08 |
| NCT04592653 | Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2020-09-30 | 2024-12 | 2024-07 |
| NCT04144517 | A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer | COMPLETED | PHASE2 | 2020-02-05 | 2022-01-07 | 2021-10-08 |
| NCT03861793 | A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2) | COMPLETED | PHASE1, PHASE2 | 2019-02-26 | 2023-03-01 | 2023-03-01 |
| NCT02799095 | A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors | COMPLETED | PHASE1, PHASE2 | 2016-09-14 | 2023-08-02 | 2023-03-27 |